MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide by Reza, M et al.
MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting
and facilitating rare and neuromuscular disease research worldwide
Mojgan Reza a, Daniel Cox a, Lauren Phillips a, Diana Johnson b, Vaishnavi Manoharan b,
Michael Grieves a, Becky Davis a, Andreas Roos a, Jennifer Morgan b, Michael G. Hanna c,
Francesco Muntoni b, Hanns Lochmüller a,*
a John Walton Muscular Dystrophy Research Centre, MRC Centre for Neuromuscular Diseases, Institute of Genetic Medicine, Newcastle University, Newcastle
upon Tyne, UK
b Dubowitz Neuromuscular Centre, University College London Great Ormond Street Institute of Child Health, London, UK
c National Hospital for Neurology & Neurosurgery, UCL, Queen Square, London, UK
Received 14 February 2017; received in revised form 30 June 2017; accepted 3 July 2017
Abstract
Neuromuscular diseases are both genetic and acquired conditions resulting in progressive muscle weakness and wasting which lead to disability
and reduced survival. The availability of high-quality human biomaterial is crucial to support biomedical research with potential applications at
all stages of development, from molecular pathophysiology to drug discovery, clinical trials and evaluation of biomarkers. Although significant
progress has been made over the last few years in the diagnosis of these rare conditions, the genetic defect and underlying pathological abnormality
remain unknown in approximately 1/3 of cases. Moreover, to date no definitive cure is available for most neuromuscular disorders, nor are there
sufficiently reliable and specific biomarkers to monitor disease progression and response to treatment. This is in part due to the rarity and genetic
heterogeneity of neuromuscular diseases and the lack of access to patient samples. The availability of the national MRC Centre Biobank for
Neuromuscular Diseases in Newcastle and London has addressed this bottleneck and supported neuromuscular research. Nine years after the
establishment of the MRC Centre Biobank, many high profile research publications have highlighted the positive impact of neuromuscular
biobanking for translational research and proven this facility to be a unique repository source for diagnostics, basic science research, industry, drug
development, and therapy.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
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1. Introduction
NMDs represent a major cause of mortality and morbidity in
children and adults. NMDs collectively affect an estimated
500,000 EU citizens and result in significant costs for families
and healthcare systems. Many institutions and organisations,
including the MRC Centre for Neuromuscular Diseases, have
reduced the gap between science discoveries and patient benefit
by establishing a multidisciplinary translational research
activity in these disabling disorders. The MRC Centre for
Neuromuscular Diseases is a partnership between the UCL
Institutes of Child Health and Institute of Neurology, and the
University of Newcastle upon Tyne and is one of the MRC’s
translational research centres in the UK. The MRC Centre for
Neuromuscular Diseases Biobank is an integrated resource
operating between Newcastle and London and builds one the
five core activities of the MRC Centre for Neuromuscular
Diseases to support the translational program of the centre. The
biobank was established in 2008 and obtained funding by the
MRC initially for five years (2008–2013) with an extension of
a further five years until 2018. Both biobanks collect, preserve
and distribute human samples to facilitate research in various
areas of neuromuscular research. In 2010, the MRC Biobank
was recognised as an official member of the EuroBioBank
(http://www.eurobiobank.org/en/information/info_institut.htm)
with a regularly published catalogue of samples made available
for research. Currently, the MRC Biobank has assembled a
* Corresponding author. John Walton Muscular Dystrophy Research Centre,
University of Newcastle, International Centre for Life, Central Parkway,
Newcastle upon Tyne, NE1 3BZ, UK.
E-mail address: hanns.lochmuller@ncl.ac.uk (H. Lochmüller).
https://doi.org/10.1016/j.nmd.2017.07.001
0960-8966/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
Available online at www.sciencedirect.com
Neuromuscular Disorders 27 (2017) 1054–1064
www.elsevier.com/locate/nmd
ScienceDirect
collection of more than 13,000 anonymised rare disease
samples mostly derived from NMD patients that are linked to
patient data using a biobank ID and secure database. The
collection includes DNA, muscle and skin biopsies, myoblasts,
fibroblasts, urine, RNA, serum and plasma (Table 1, Fig. 1).
Patient data are constantly updated against genetic reports.
Samples are obtained from patients and family members with a
confirmed or suspected diagnosis, such as muscular dystrophy,
congenital myopathy, Charcot-Marie-Tooth disease and
mitochondrial myopathy (Table 2 and Fig. 2). Notably, the
collected samples can be requested by researchers carrying out
studies on approval by the biobank’s access committee. In
addition, samples are distributed under a strict governance
framework, with an internal application form and institutional
Material Transfer Agreement (MTA) and only after having
verified the ethical approval of the recipient laboratory for the
planned study where required.
1.1. Ethical approval and governance arrangements
The ethics application for London has received a positive
opinion by the ‘NHS National Research Ethics Service,
Hammersmith and Queen Charlotte’s and Chelsea Research
Ethics Committee’ with REC reference number 06/Q0406/33,
and for Newcastle by the ‘Newcastle and North Tyneside 1
Research Ethics Committee’ with REC reference number
08/HO906/28 + 5, which include consent and assent forms and
patient information sheets adapted for different ages. These
processes help to ensure that research is performed within the
scope that is explained to the research participants and their
carers. Transparent access arrangements are in place for use of
the stored samples in research (see below).
1.2. Biobank samples, referral and consent
The samples are processed for storage with informed and
signed consent of either the patients or their legal guardian,
where an individual is considered unable to give consent. In
addition, a referral form signed by the referring clinician
accompanies each sample confirming the origin of the sample
and includes core data including name, date of birth, gender,
phenotype, ambulatory status, genetic results and confirmed or
suspected diagnosis (Supplementary data S1–S4). Samples will
not be processed and used in the absence of written informed
consent. Patients participating in international studies, who do
not speak English, need to be provided with information and
consent forms in their own language which are provided in the
research protocols of such studies. Muscle biopsies acquired for
biobanking purposes are ‘left overs’ to diagnostic requirements
and are collected at the time of routine procedures indicated by
clinical need. Skin biopsies, blood, urine or other relevant fluids
are mostly attained during routine clinical consultations in our
centres, or if possible, opportunistically during the muscle
biopsy procedure. Moreover, samples may be collected at
clinical appointments as part of clinical trials and studies. Body
fluid collection for biomarker studies including whole blood
and urine are an integral component of the biobank, in order to
address the lack of access to patient’s biomaterial for both
academic research and industry. Specimens from patients in
various stages of disease, as well as, samples derived from
control donors are collected in the search for biomarkers, as
predictors, biological indicators or tests that will monitor
disease progression. Similarly, routine whole blood collection
and subsequent DNA/RNA extraction facilitates gene discovery
in patients with neuromuscular conditions and unknown genetic
defects. In addition to locally collected samples, various
biomaterials may be obtained from other centres, both in the
UK and abroad.
1.3. Submission of samples to the biobank from other centres
The majority of sample submission comes from local
services and from studies carried out in London and Newcastle.
In addition, the MRC Biobank encourages submission of
biological samples from elsewhere, in particular samples
obtained through multi-centre studies including natural history
studies, clinical trials and collaborative studies with industry.
The same strict, ethical and legal principles as for the local
submissions are applied to the external submissions. External
samples and patient data are held in strict confidence and
identifiable information is not made available to anyone outside
of the biobank. Standard Operating Procedures (SOPs) on
sample collection, handling, sampling conditions for each type
of sample and advice on material transport are provided by the
biobank staff. The biobank supports researchers in developing
study-specific protocols and SOPs and offers scientific advice
for the best choice and use of biomaterials for their studies.
Generally, shipment of samples and shipping cost is the
responsibility of the sender, unless otherwise agreed with the
biobank.
1.4. Disease classification
Biobanks both in Newcastle and London, collectively
preserve samples deriving from more than 100 different
Table 1
Sample types stored in the biobank.
Sample type London Newcastle
CD133+ cells 12 0
Muscle derived fibroblasts 7 0
Fibroblasts 806 877
Myoblasts 681 713
Sorted CD56+ myoblasts 3 0
Frozen muscle 239 0
Frozen skin 7 0
Immortalised fibroblasts 1 27
Immortalised myoblasts 13 20
Peripheral blood lymphocytes 30 0
PBMCs 16 0
Plasma 245 789
Serum 303 2042
PBLs-transformed 55 0
Muscle derived pericytes 1 0
Synovial cells 10 0
Urine 74 777
DNA 126 4653
RNA 0 770
TOTAL 2629 10668
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conditions with known genetic defects. As shown in Fig. 2, a
superordinate classification of the diseases includes myotonic
dystrophy with more than 5000 samples, followed by muscular
dystrophy samples and other rare diseases such as
mitochondrial disorders, ataxia, motor neuron disease,
congenital myopathy and myasthenic syndrome. A precise
classification of subgroups is outlined in Table 2.
1.5. Sample handling and data management
Samples transported to Newcastle or London are processed
using Standard Operating Procedures (SOPs) adapted from
current EuroBioBank SOPs or protocols developed in the
biobanks. The required data are recorded in the respective
individual databases and stored samples are identified by a
‘linked-anonymised’ unique laboratory code which is allocated
to each sample upon arrival, linking samples and clinical
information to patients. In order to protect patient’s privacy, all
identifying information is held in a locked and access-restricted
filing cabinet. Only authorised biobank staff has access to the
‘key’ for relinking the participants’ identifying information
with their data and samples. It is necessary to retain this link
with identifying information to allow follow-up of research
findings or feedback relevant, new information such as a
confirmed diagnosis to the patients via their referring
clinicians.
1.6. Catalogue of samples
Collected samples with a confirmed diagnosis are available
to users via EuroBioBank catalogue (http://www.eurobiobank
.org/en/services/Catalogue Home.html). The catalogue lists
available samples by type of biomaterial or disease name and
code according to ICD-10 [1], OMIM [2] and Orphanet [3]
Classification. Once a sample has been located in the catalogue,
it can be requested from the biobank in Newcastle or London.
Fig. 1. Sample types stored in the biobank. The Figure shows the type and number of stored samples available in both biobanks and their development over time.
The number of collected biospecimens such as blood DNA and RNA, as well as, serum and plasma for biomarker studies were consistently increased due to routine
sample collection in the neuromuscular clinics in both centres.
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Additional clinical and genetic information including mutation,
age and other relevant data -as far as available- can be requested
from the biobank team. The MRC Biobank is fully incorporated
in international biobanking frameworks such as RD-Connect
[4], BBMRI-ERIC [5,6] and EuroBioBank [7]. RD-Connect is
a unique global infrastructure project that connects biobanks,
registries, databases and clinical bioinformatics data used in
rare disease research into a central resource for researchers
worldwide. BBMRI-ERIC (Biobanking and Biomolecular
Resources Research Infrastructure – European Research
Infrastructure Consortium) is an infrastructure with sustainable
funding from European member states covering a wide
spectrum of biobanks including bioresources for all diseases,
irrespective of whether they are considered common or rare, as
well as population-based cohort studies. Within RD-Connect
and in partnership with BBMRI-ERIC, a new online
RD-Connect sample catalogue for rare disease biobanks has
been developed. The catalogue is based upon the MIABIS
Table 2
Classification of the diseases.
Disease Count Disease Count
Adult-Onset Cerebellar Ataxia Due To Cabc1/Adck3 Mutation 1 Limb-Girdle Muscular Dystrophy Type 2I 73
Adams Oliver Syndrome 2 Limb-Girdle Muscular Dystrophy Type 2K 18
Age-Related Macular Degeneration 10 Limb-Girdle Muscular Dystrophy Type 2L 26
Atypical Hemolytic-Uremic Syndrome 2 Lipid Storage Myopathy 60
Autosomal Dominant Motorneurone Disease 2 Marinesco-Sjögren Syndrome 6
Becker MD 403 MELAS Syndrome 4
Becker Muscular Dystrophy Female Carrier 32 MERRF Syndrome 7
Behr Syndrome 1 Minicore Myopathy With External Ophthalmoplegia 15
Benign Fasciculation Syndrome 1 Mitochondrial Complex I Deficiency 2
Brown-Vialetto-Van Laere Syndrome; Bvvls 4 Mitochondrial Complex II Deficiency 1
Bethlem Myopathy 126 Mitochondrial Complex III Deficiency 3
Central Core Disease 46 Mitochondrial Disorder 31
Carnitine Palmitoyltransferase II Deficiency, Infantile 1 Mitochondrial Myopathy 9
Centronuclear Myopathy 3 Morphea Sclerosis 1
Charcot-Marie-Tooth Ddisease (Not Specified) 1 Motor Predominant Axonal Peripheral Neuropathy 1
Charcot-Marie-Tooth Disease, X-Linked 2 Miyoshi Myopathy 231
Muscular Dystrophy, Congenital, 1C; MDC1C 20 Multi-Minicore Myopathy 2
Coenzyme Q10 Deficiency 2 Muscle Eye Brain Disease 18
Congenital Myopathy Due To SEPN1 Mutation 9 Multiple Acyl-Coa Dehydrogenase Deficiency 4
Congenital Myasthenic Syndromes 366 Muscular Dystrophy, Congenital Merosin-Deficient, 1A 57
Control 289 Myasthenia Gravis 2
Distal Myopathy 1 MYH7 Related Myopathy 6
DMD/BMD Intermediate 39 Myotubular Myopathy 20
DMD/BMD Intermediate Female Carrier 4 Myofibrillar Myopathy 12
Duchenne Muscular Dystrophy 1899 Myotonia Congenita 2
Diabetes-Deafness Syndrome, Maternally Transmitted 3 Myotonic Dystrophy Type 1 5116
Duchenne Muscular Dystrophy Female Carrier 140 Myotonic Dystrophy, Unspecified 4
Episodic Ataxia Type 2 2 Nemaline Myopathy 16
Emery-Dreifuss Muscular Dystrophy 19 Neuroferrinopathy 122
Enhanced S-Cone Syndrome 1 Neutral Lipid Storage Disease With Myopathy 2
Epilepsy 1 Non-Age Related Macular Degeneration 1
Facioscapulohumeral Muscular Dystrophy 50 Oculopharyngeal Muscular Dystrophy 6
Facioscapulohumeral Muscular Dystrophy Type 2 126 Oculopharyngodistal Myopathy 4
Friedreich Ataxia 28 Optic Atrophy 4
Hereditary Sensory And Autonomic Type 1 54 Optic Atrophy 1 20
Hereditary Inclusion Body Myopathy 1 Pompe Disease (Glycogen Storage Disease) 7
Idiopathic Pulmonary Arterial Hypertension 7 Progressive External Ophthalmoplegia (Polg2) 2
Inclusion Body Myositis 2 Retinitis Pigmentosa 12
Inherited Peripheral Neuropathy CMT2 3 Sjögren Syndrome 2
Inclusion Body Myopathy With Early-Onset Paget Kennedy
Disease
32
1
Scoliosis 27
Leber Hereditary Optic Neuropathy 16 Ryanodine Receptor 1 Related Myopathy 8
Leukoencephalopathy With Vanishing White Matter 1 Severe Early-Onset Axonal Neuropathy Due To MFN2 3
Limb-Girdle Muscular Dystrophy (Not Specified) 59 Spinal Muscular Atrophy Type 1 9
Limb-Girdle Muscular Dystrophy Type 1B 8 Spinal Muscular Atrophy Type 2 6
Limb-Girdle Muscular Dystrophy Type 1C 8 Spinal Muscular Atrophy Type 3 7
Limb-Girdle Muscular Dystrophy Type 2A 59 Spinal Muscular Atrophy, Unspecified 6
Limb-Girdle Muscular Dystrophy Type 2B 1841 Spinal Muscular Atrophy With Respiratory Distress 1
Limb-Girdle Muscular Dystrophy Type 2C 10 Titinopathy/Myofibrillar Myopathy 8
Limb-Girdle Muscular Dystrophy Type 2E 2 Ullrich Congenital Muscular Dystrophy 19
Limb-Girdle Muscular Dystrophy Type 2F 1 Wolfram Syndrome 1 8
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standard and provides users with a searchable and filterable
sample dataset, assembled from multiple rare disease biobank
sample collections, making biobank data FAIR (Findable,
Accessible, Interoperable and Reusable) [8]. The new online
catalogue provides researchers with a more detailed and
accurate collection of biobank sample data, giving users the
ability to filter multiple sample data fields or to search for
available biomaterials using specific terms such as disease
name or classification codes.
1.7. Eligibility, access and application process
Samples are accessible to research groups based in the UK
and elsewhere around the world. Applicants should be
employees of a recognised academic, research or clinical
institution; or employed or contracted by a commercial
organisation working towards developing diagnosis and
treatment for neuromuscular or other rare disorders. Samples
can also be made available to scientists who are interested in
basic science research i.e. in research of muscle structure and
function. Researchers who wish to access the collection should
initially contact the biobank coordinator directly. An
‘Application for use of samples for research’ form
(Supplementary data S6–S8) provided by the biobank in
Newcastle or London, should be completed by applicants
giving a brief outline of the proposed study and for what
purpose the samples will be used, followed by the number and
type of samples required. Two members of the access
committee will assess the suitability of the application and the
biobank coordinator or relevant biobank member of staff will
respond to the applicant. Upon approval of the application
form, the applicant will be required to complete a MTA form
and agree to the conditions of access set out within the
agreement and return a signed e-copy to the Intellectual
Property and Legal Services Department at Newcastle
University or UCL. Samples supplied to the applicant from the
biobank collection can only be for the purposes stated in the
application form, accepted by the access committee and
described in the MTA. Research publications or presentation
using data or samples from the biobank should include an
acknowledgement to the MRC Centre Biobank in Newcastle or
London. These publications must also be reported to the
biobank coordinator for reporting purposes. The applicant may
be asked to cover the costs of retrieving, processing and
dispatching samples.
1.8. Organisation, responsibilities and administration of the
biobank
Upon receipt of the full application, a member of biobank
staff will check to ensure that the samples requested are
available and that all required information has been supplied by
the applicant. If samples are not available the applicant will be
notified and possible alternatives discussed. If any information
is missing from the application the applicant will be asked to
supply this before the application will be considered further.
Access to samples is overseen by an access committee which is
composed of the investigators of the MRC Centre for
Fig. 2. Classification of the diseases into large subgroups. Distribution of diseases among biobank samples. The size of the rectangles is proportional to the number
of samples. Related diseases are summarised under generic terms in different colors. Undiagnosed samples are not shown.
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Neuromuscular Diseases (http://www.cnmd.ac.uk/research/
research_groups). The function of the access committee is to
ensure that measures are in place to achieve compliance with
the agreed procedures, protect the interests of patients and the
biobank, and to oversee sample provision for research purposes.
It does not act in as a scientific review board. The access
committee reviews the eligibility of the proposed study and
decide whether information provided by the applicants would
justify releasing samples, some of which are rare or even
unique. The committee also oversees whether the applicant of a
research project is an approved and recognised researcher. The
laboratory team is responsible for implementation and day to
day running of the biobank including processing and archiving
samples, recording data, establishing primary cultures,
extracting DNA and preparing samples for shipment. The team
also acts as a central contact for distribution of material and
data as required by project partners and responsible for
maintaining stocks of biological material, records and datasets,
as well as undertaking changes to database, protocols and
SOPs. Additionally, the laboratory team undertakes regular
quality control and maintenance of laboratory equipment to
safeguard the quality of samples. Ethical issues are processed
by the biobank coordinator who assists with relevant ethical
approval and procedures. The coordinator facilitates and
coordinates the daily clinical trial activities in collaboration
with legal departments and sponsors.
1.9. National and international networking and sample
distribution
Many research programs have benefited from specimens
provided by the MRC Biobank. More than 700 research
projects outside the MRC Centre have received samples for
research confirming the national and international science
resource and collaborative links of the MRC Centre. Fig. 3
shows research centres that have received samples from both,
Newcastle and London biobanks. The MRC Biobank has also
been critical in supporting research activities through the
collection of samples for externally funded projects such as
Optimistic and NeurOmics, natural history studies and clinical
trials. Natural history studies and clinical trials supported by the
biobank are listed in Table 3. On request and depending on the
individual study or collaboration, the biobank principal
investigators may assist with advice on grant writing
procedures for external projects that involve the biobank.
1.10. Gene discovery
Novel gene identification is supported by the MRC Biobank
through the collection of blood samples and by supplying high
quality DNA for whole exome (WES), whole genome (WGS)
and Sanger sequencing. By the same token, new variants
responsible for NMDs have been identified and published
through use of samples derived from patients. For instance,
mutations in DPAGT1, ALG14 and ALG2 have been shown to
be causative for different subtypes of congenital myasthenic
syndrome and the importance of asparagine-linked protein
glycosylation for proper functioning of the neuromuscular
junction [9]. Detection of mutations in ANO10 indicates that
ANO10 defects cause secondary low COQ10 and it has been
proposed that SCAR10 patients may benefit from COQ10
supplementation [10]. Mutations in the Synaptotagmin 2 C2B
domain represent an important cause of presynaptic congenital
myasthenic syndromes and link them with hereditary motor
Fig. 3. Distributed samples within the UK and worldwide. Worldwide distribution of Newcastle MRC Centre Biobank samples. Countries that have received samples
from the biobank include the UK, USA, Japan, Australia, Spain, France, Germany and Italy.
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axonopathies [11]. Two missense mutations residing in the
N-terminal agrin domain were identified which resulted in
reduced acetylcholine receptors clustering activity of agrin in
vitro [12]. A publication has shown that homozygous missense
mutations in EXOSC8 cause progressive and lethal neurological
disease in 22 infants from three independent pedigrees [13].
Recessive and dominant mutations in COL12A1 have shown to
cause a novel EDS/myopathy overlap syndrome in humans and
mice [14]. It has been reported that mutations in the MYO9A
gene may affect the presynaptic motor axon in patients with
congenital myasthenic syndrome [15]. Table 4a and 4b
highlights some more examples of genes and their functionality,
which have been identified using biobank samples.
1.11. Biomarker development and natural history studies
Collection of biomaterials for biomarker- and natural history
studies are two core translational activities of the biobank and
current research is dedicated to identification of potential
protein biomarkers for prediction of disease course,
complications or response to therapy in NMDs. The use of
-omics and other technologies have resulted in a considerable
number of publications, many of which proposed several
circulating biomarkers for the early detection and diagnosis in
NMDs. These findings hold promise for the development of
new clinical management for these patients. Examples of these
studies include MMP-9 [16]; CA3, MYL3, MDH2, ETFA [17];
ADAMTS5 [18]; CA1, FBLN1, GC, GSN [19], miRNAs in
Duchenne muscular dystrophy [20] and in spinal muscular
atrophy, with cross validation in SMA mouse models following
therapeutic intervention [21] (Table 5). In the same way,
obtaining maximum value to support drug development
programs depends on conducting natural history studies before
potential therapeutic agents are identified for development.
Well conducted natural history studies are important for
understanding the range of phenotype manifestations, the
aetiology and progression of rare diseases.
Table 3
Examples of clinical trials and natural history studies supported by the biobank.
Study Time period Description
Vision DMD 2017–present A phase IIb randomized, double-blind, placebo- and active-controlled study to assess the efficacy and
safety of VBP15 in ambulatory boys with Duchenne muscular dystrophy
AMO Pharma (NCT02858908) 2016–present A single-blind, phase 2 study to evaluate the safety and efficacy of tideglusib 400 mg Or 1000 mg for
the treatment of adolescent and adult congenital and juvenile-onset myotonic dystrophy
GNE Phase 3b (NCT02736188) 2016–present A phase 3b open-label extension study to evaluate the safety and efficacy of aceneuramic acid
extended-release (Ace-ER) tablets in patients with GNE or hereditary inclusion body myopathy
Disease Translation in DMD 2016–present Neuromuscular Rare Disease Translational Research in patients with Duchenne muscular dystrophy
Pfizer DMD Study 2015–present Phase 1b/2, double-blind, dose escalation study to evaluate the safety and efficacy of PF-06252616
administered to ambulatory boys with Duchenne muscular dystrophy
BMD Natural History Study
(NCT01539772)
2015–present Becker muscular dystrophy – a natural history study to predict efficacy of exon skipping
Testosterone Study
(NCT02571205)
2015–present Observational outcomes in testosterone treatment of pubertal delay in Duchenne muscular dystrophy
GNE SAER (NCT02377921) 2015–present A phase 3 randomized, double-blind study to evaluate the efficacy and safety of sialic acid extended
release tablets in patients with GNE or hereditary inclusion body myopathy
PhenoDM1 (NCT02831504) 2015–present PhenoDM1 - myotonic dystrophy type 1 (DM1) deep phenotyping to improve delivery of personalised
medicine and assist in the planning, design and recruitment of clinical trials
GNE Natural History Study
(NCT01784679)
2014–present Hereditary inclusion body myopathy-patient monitoring program (HIBM-PMP): a registry and
prospective observational natural history study to assess HIBM disease
NeoGAA Extension 2014–present An open-label, multicenter, multinational extension study of the long-term safety and pharmacokinetics
of repeated weekly infusions of NeoGAA in patients with pompe disease
FSHD NH Study 2014–present A multi-centre collaborative study on the clinical features, expression profiling, and quality of life of
infantile onset facioscapulohumeral muscular dystrophy
OPTIMISTIC 2014–present Observational prolonged trial in myotonic dystrophy type 1 to improve quality of life standards
SKIP-NMD 2014–2016 A 2-part, randomized, double-blind, dose-titration, safety and tolerability study (part 1) followed by an
open-label efficacy and safety evaluation (part 2) of SRP-4053 in patients with Duchenne muscular
dystrophy amenable to exon 53 skipping
FOR-DMD (NCT01603407) 2013-present An international, multi-centre study to compare the benefits and side effects of the three most widely
prescribed steroid treatments in children with Duchenne muscular dystrophy
Natural History of
Dysferlinopathy (NCT01676077)
2012-present A collaborative project co-ordinated via the TREAT-NMD network and the Jain foundation and
utilising the strengths and well defined populations already characterised in Europe and the US
DMD Heart Protection Trial 2010–2018 A double-blind, randomised multi-centre, placebo-controlled trial of combined ACE-inhibitor and
beta-blocker therapy in preventing the development of cardiomyopathy in males with DMD without
echo-detectable left ventricular dysfunction
CMT Natural History Study 2009–2019 Charcot-Marie-Tooth disease and related disorders: a natural history study
AFM Natural History study
(NCT 02780492)
2009–2016 Developing tools for assessing the natural history of ambulant and non-ambulant DMD individuals to
assist in antisense oligomer clinical trials
PTC124 Trial 2009 A phase 2a study of ataluren (PTC124) in non-ambulatory patients with nonsense–mutation-mediated
Duchenne/Becker muscular dystrophy
AVI-4658 Trial (phase 1) 2009 Safety and efficacy study of antisense oligonucleotides in Duchenne muscular dystrophy
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1.12. Translational research
The MRC Biobank has been instrumental in providing cells
for muscle stem cell research, focused on the characterisation
of optimal stem cells, as well as, in development of viral gene
therapy vector for autologous cell transplantation in muscular
dystrophy and the further characterisation of molecular
pathways relevant for muscle stem cell function (Table 6). In
addition, cells from the MRC Centre have supported studies for
target identification for splicing modification or allele selective
silencing using antisense oligonucleotides for collagens
VI-related muscular dystrophy, RYR1-related myopathies,
SLPTC1 neuropathies and spinal muscular atrophy, as well as,
for gene editing using CRISPR/Cas9 (unpublished data).
Fibroblasts lines obtained from patients with DMD were used
to generate human induced pluripotent stem cells (iPSCs)
cardiomyocytes harbouring DMD mutations to enable
therapeutic approaches such as gene therapy and exon skipping
to be tested in human cardiomyocytes [22]. Other fibroblasts
cell lines obtained from patients’ biopsies carrying the most
common mitochondrial mutations were subjected to non-
integrating Sendai virus mediated reprogramming [23].
Established stable iPSCs lines were validated for positive
expression of pluripotency factors and formation of three germ
layers: mesoderm, endoderm and neuroectoderm. Validated cell
lines were subsequently karyotyped to exclude lines with
Table 4
Publications on gene discovery and function using biobank samples.
Title (gene discovery) Reference Journal
Identification of mutations in the MYO9A gene in patients with congenital myasthenic syndrome (O’Connor, Topf et al. 2016) Brain
Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or ‘classical’ congenital
myopathy
(Zaharieva, Thor et al. 2016) Brain
Dihydropyridine receptor (DHPR, CACNA1S) congenital myopathy (Schartner, Romero et al. 2016) Acta Neuropathol.
Novel mutations expand the clinical spectrum of DYNC1H1-associated spinal muscular atrophy (Scoto, Rossor et al. 2015) Neurology
Phenotypic and molecular insights into spinal muscular atrophy due to mutations in BICD2 (Rossor, Oates et al. 2015) Brain
A large deletion affecting TPM3, causing severe nemaline myopathy (Kiiski, Lehtokari et al. 2015) JND
ANO10 mutations cause ataxia and coenzyme Q10 deficiency (Balreira, Boczonadi et al. 2014) J Neurol.
Synaptotagmin 2 mutations cause an autosomal-dominant form of lambert-eaton myasthenic
syndrome and nonprogressive motor neuropathy
(Herrmann, Horvath et al. 2014) Am J Hum Genet.
Agrin mutations lead to a congenital myasthenic syndrome with distal muscle weakness and atrophy (Nicole, Chaouch et al. 2014) Brain
EXOSC8 mutations alter mRNA metabolism and cause hypomyelination with spinal muscular
atrophy and cerebellar hypoplasia
(Boczonadi, Muller et al. 2014) Nat Commun.
Mutations in the mitochondrial citrate carrier SLC25A1 are associated with impaired neuromuscular
transmission
(Chaouch, Porcelli et al. 2014) JND
Loss of function mutations in MICU1 cause a novel disorder affecting brain and muscle and reveal
primary alterations in mitochondrial Ca2+ signalling as a new disease mechanism
(Logan, Szabadkai et al. 2014) Nat Genet.
Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2 (Foley, Menezes et al. 2014) Brain
COX10 mutations resulting in complex multisystem mitochondrial disease that remains stable into
adulthood
(Pitceathly, Taanman et al. 2013) JAMA Neurol.
Identification of KLHL41 mutations implicates BTB-kelch-mediated ubiquitination as an alternate
pathway to myofibrillar disruption in nemaline myopathy
(Gupta, Ravenscroft et al. 2013) Am J Hum Genet.
Nebulin (NEB) mutations in a childhood onset distal myopathy with rods and cores uncovered by
next generation sequencing
(Scoto, Cullup et al. 2013) Eur J Hum Genet.
Congenital myasthenic syndromes due to mutations in ALG2 and ALG14 (Cossins, Belaya et al. 2013) Brain
Isoprenoid synthase domain containing gene mutations are a common cause of congenital and limb
girdle muscular dystrophies
(Cirak, Foley et al. 2013) Brain
Pontocerebellar hypoplasia type 1: clinical spectrum and relevance of EXOSC3 mutations (Rudnik-Schoneborn,
Senderek et al. 2013)
Neurology
Mutations in B3GALNT2 cause congenital muscular dystrophy with hypoglycosylation of
alpha-dystroglycan
(Stevens, Carss et al. 2013) Am J Hum Genet.
Mutations in BICD2 cause dominant congenital spinal muscular atrophy and hereditary spastic
paraplegia
(Oates, Rossor et al. 2013) Am J Hum Genet.
Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular
dystrophies associated with hypoglycosylation of alpha-dystroglycan
(Carss, Stevens et al. 2013) Am J Hum Genet.
Mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy (Ravenscroft, Miyatake et al. 2013) Am J Hum Genet.
NDUFA4 mutations underlie dysfunction of a cytochrome C oxidase subunit linked to human
neurological disease
(Pitceathly, Rahman et al. 2013) Cell Rep.
SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function (Yoshida-Moriguchi, Yu et al. 2010) Science
An RYR1 mutation associated with malignant hyperthermia is also associated with bleeding
abnormalities
(Lopez, Byrne et al. 2016) Sci Signal.
Adenovirus-mediated expression of myogenic differentiation factor 1 (MyoD) in equine and human
dermal fibroblasts enables their conversion to caffeine-sensitive myotubes
(Fernandez-Fuente,
Martin-Duque et al. 2014)
Neuromuscul
Disord.
RyR1 deficiency in Congenital myopathies dDisrupts excitation-contraction coupling (Zhou, Rokach et al. 2013) Hum Mutat.
Establishment of a human skeletal muscle-derived cell line: biochemical, cellular and
electrophysiological characterization
(Rokach, Ullrich et al. 2013) Biochem J.
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chromosomal rearrangements. Validated human iPSCs has
been successfully differentiated into multinucleated skeletal
muscles via stepwise differentiation protocol. The
differentiation culture system contains defined myogenic
factors, which allow recapitulating developmental stages of
myogenesis. Each stage of differentiation including: late
presomatic mesoderm specification, myoblast formation, cell
cycle withdrawal, commitment and cell fusion to form
multinucleated myotubes is assessed via quantification of
differentiation markers at the RNA and protein level.
Table 5
Publications arisen from biomarker studies.
Title (biomarker identification) Reference Journal
Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to
Antisense Oligonucleotide Therapy
(Catapano, Zaharieva et al. 2016) Mol Ther Nucleic
Acids
Global serum glycoform profiling for the investigation of dystroglycanopathies & congenital disorders
of glycosylation
(Heywood, Bliss et al. 2016) Mol Genet Metab
Rep.
Altered levels of microRNA-9, -206, and -132 in spinal muscular atrophy and their response to
antisense oligonucleotide
(Catapano, Zaharieva et al. 2016) Therapy. Mol Ther
Nucleic Acids
Correlation of utrophin levels with the dystrophin protein complex and muscle fibre regeneration in
Duchenne and Becker muscular dystrophy muscle biopsies
(Janghra, Morgan et al. 2016) PLoS One
Deep RNA profiling identified CLOCK and molecular CLOCK genes as pathophysiological signatures
in collagen VI myopathy
(Scotton, Bovolenta et al. 2016) J Cell Sci.
204th ENMC international workshop on biomarkers in Duchenne muscular dystrophy 24–26 January
2014, Naarden, The Netherlands
(Ferlini, Flanigan et al. 2015) Neuromuscul
Disord.
Epigenetic changes as a common trigger of muscle weakness in congenital myopathies (Rokach, Sekulic-Jablanovic
et al. 2015)
Hum Mol Genet.
The EuroBioBank Network: 10 years of hands-on experience of collaborative, transnational biobanking
for rare diseases
(Mora, Angelini et al. 2015) Eur J Hum Genet.
Dystrophin quantification: biological and translational research implications (Anthony, Arechavala-Gomeza
et al. 2014)
Neurology
Muscle proteomics reveals novel insights into the pathophysiological mechanisms of collagen VI
myopathies
(De Palma, Capitanio et al. 2014) J Proteome Res.
Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular
dystrophies
(Ayoglu, Chaouch et al. 2014) EMBO Mol Med.
Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy (Zaharieva, Calissano et al. 2013) PLoS One
Flow cytometry for the analysis of a-dystroglycan glycosylation in fibroblasts from patients with
dystroglycanopathies
(Stevens, Torelli et al. 2013) PLoS One
Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular dystrophy (Zaharieva, Calissano et al. 2013) PLoS One
Table 6
Publications on translational research supported by the biobank.
Title (translational research) Reference Journal
Autologous skeletal muscle derived cells expressing a novel functional dystrophin provide a
potential therapy for Duchenne muscular dystrophy
(Meng, Counsell et al. 2016) Sci Rep.
Spell checking nature: versatility of CRISPR/Cas9 for developing treatments for inherited
disorders
(Wojtal, Kemaladewi et al. 2016) Am J Hum Genet.
The effect of the muscle environment on the regenerative capacity of human skeletal muscle
stem cells
(Meng, Bencze et al. 2015) Skelet Muscle
Gene expression profiling identifies molecular pathways associated with collagen VI deficiency
and provides novel therapeutic targets
(Paco, Kalko et al. 2015) PLoS One
The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy
mice
(Whitmore, Fernandez-Fuente
et al. 2014)
Hum Mol Genet.
The human desmin promoter drives robust gene expression for skeletal muscle stem
cell-mediated gene therapy
(Jonuschies, Antoniou et al. 2014) Curr Gene Ther.
BMI1 enhances skeletal muscle regeneration through MT1-mediated oxidative stress protection
in a mouse model of dystrophinopathy
(Di Foggia, Zhang et al. 2014) J Exp Med.
Mutation of the human mitochondrial phenylalanine-tRNA synthetase causes infantile-onset
epilepsy and cytochrome c oxidase deficiency
(Almalki, Alston et al. 2014) Biochim Biophys Acta.
Targeted exon skipping to correct exon duplications in the dystrophin gene (Greer, Lochmuller et al. 2014) Mol Ther Nucleic Acids
Antisense suppression of donor splice site mutations in the dystrophin gene transcript (Fletcher, Meloni et al. 2013) Mol Genet Genomic Med.
Mitochondrial DNA deletions in muscle satellite cells: implications for therapies (Spendiff, Reza et al. 2013) Hum Mol Genet.
Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent
stem cells-cardiomyocytes harbouring DMD mutations
(Dick, Kalra et al. 2013) Mol Ther Nucleic Acids
Two new protocols to enhance the production and isolation of human induced pluripotent stem
cell lines
(Dick, Matsa et al. 2011) Stem Cell Res.
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Maturation is performed by reducing knock-out serum
replacement or supplementing media with selected serum
components. Current work, in collaboration with UCL Eastman
Dental Institute specialising in materials and tissue engineering,
focuses on transferring monolayer culture conditions into
scaffold-facilitated 3D culture.
1.13. Collaboration with industry
The MRC Biobank has been collaborating with an
increasing number of pharmaceutical companies involving
biomarker studies. Biobank samples have been provided to
industrial partners such as Pfizer [24,25] and Bristol-Myers-
Squibb for identification of serum and urine biomarkers
(manuscript submitted). Due to high number of requests, the
biobank has improved its access procedures and recently
introduced a ‘cost recovery plan’. Cost recovery involves the
sharing of costs incurred for sample collection and
management. When third parties apply to use the stored
samples, they may be asked to provide money to the biobank to
help cover the sample collection and management costs. These
charges are applied to reduce some of the storage costs and
support the availability of funds for ongoing sample collection
and preservation; however, no profit is generated from the use
or storage of biobank samples. The charges are under regular
review to ensure that it is being used appropriately and fairly.
1.14. Additional financial and institutional support
Due to limited funding and increased interest in biobank as
a repository for multi-centre studies, the biobank is seeking
additional support from internal and external sources. For
instance, the Jain Foundation has funded technician time and
consumables to process and store large numbers of samples
from their multi-centre outcome study. Several research groups
that use the services of the biobank regularly include funding
for biobanking in their grant applications which cover some of
the biobank running cost.
2. Discussion
Given the rarity, heterogeneity and complexity of
neuromuscular disorders, as well as considerable morbidity and
mortality, there is great need for establishing dedicated
infrastructures to facilitate research. In cooperation with other
European centres for neuromuscular diseases and associated
biobanks, the MRC Biobank UK may provide an example that
such facilities enable and promote research leading to improve
diagnosis and treatment. Membership in European networks
and coordinated projects such as EuroBioBank, BBMRI and
RD-Connect strengthens visibility and supports quality
assurance, connecting the biobank and researchers worldwide.
MRC Biobank samples and data are a relevant and important
source for researchers working in academia and industry,
particularly to improve the diagnosis and treatment of patients
with rare neuromuscular disorders, therefore contributing to the
IRDiRC mandate. MRC Biobank activities have led to the
collection of more than 13,000 anonymised, quality-assured
samples resulting in high profile research publications and
supporting translational research. There are clear indications
for an increase in collaboration, global networking and
openness using the biobank service. In the past few years the
MRC Biobank for Neuromuscular Diseases in the UK has
facilitated successful research in the field of neuromuscular
disorders. Within the first years of its establishment, the
biobank surpassed all the originally established milestones and
evolved into an essential source for collection, management and
sharing of high quality samples and data. Undoubtedly without
the biobank as a central infrastructure with a secure
custodianship for data and samples, funds would be spent on
unnecessary duplication of collection and management of
samples or research projects. Moreover, samples and data may
get lost when funding for certain projects expires or the
researcher moves on to a different project or research group. In
this context, the biobank has not only the duty for the
guardianship of biospecimens and data for current studies and
projects but also for providing a platform for the benefit of
progress in research for future generations. The success of the
first nine years of biobank activities confirms that continuous
support and sustainability of the biobanks in the field of rare
diseases is an indispensable necessity, starting from the
collection of these scarce and sometimes very unique samples
through operational level and standardisation of biospecimen
processing, long-term sample storage, protection and custody
of the collected biomaterials and data management. Despite
financial support from internal resources of both centres and
partial funding acquired from external sources, the long-term
sustainability of the biobanks remains a major challenge.
Despite the recent progress in the broad-scaled analysis of
proteins in body fluids, there is still a lack in protein profiling
approaches for biomarkers of rare diseases which emphasises
the crucial role of biobank work in continuous sample and data
collection of patients with rare diseases. One of the main
challenges using biobank samples is possible variability in
collection and processing of body fluids including urine and
blood which can have dramatic effects on results and analytical
reliability. Access to high-quality specimens that are collected
and processed in a standardised way reduces potential bias and
false results. Therefore, it is essential that standard operating
procedures are in place to minimise the degree of discrepancy
in the collection and to reduce the variability. However, this is
not always possible, in particular, the quality of body fluids can
be affected by various parameters that need to be controlled
during sample collection, storage and sample preparation such
as food intake prior to sample collection, the time between
collection and processing, temperature, and even the way the
blood samples have been taken. These factors can significantly
influence the quality of samples and produce biased findings in
their proteomic profiles. The biobank is continuing to improve
the quality of samples, in particular for biomarker studies.
Biobank sample management and quality may benefit from the
implementation of a laboratory accreditation system according
to an international standard laboratory quality control system
model such as ISO 9001. Moreover, international companies
are showing a growing interest in biobank samples and the
biobank is continuing to collect and expand a broader range of
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very rare disease types and samples. Future studies would also
benefit from including more cohorts with longitudinal
follow-up samples which provides the opportunity to support
drug development, clinical trials and gene therapy approaches
giving us hope to ultimately find cure for neuromuscular and
other rare diseases.
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